BOLERO-2: EVEROLIMUS IN COMBINATION WITH EXEMESTANE IN THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR-POSITIVE ADVANCED BREAST CANCER REFRACTORY TO LETROZOLE OR ANASTROZOLE

被引：0
|
作者：
Campone, Mario [1 ]
Piccart, Martine [2 ]
Pritchard, Kathleen I. [3 ,4 ]
Xu, Cindy [5 ]
Gnant, Michael [6 ]
Neven, Patrick [7 ]
Pistilli, Barbara [8 ]
Shtivelband, Mikhail [9 ]
Provencher, Louise [10 ]
Masuda, Norikazu [11 ]
El-Hashimy, Mona [5 ]
Vittori, Luc [12 ]
Sahmoud, Tarek [5 ]
Baselga, Jose [13 ]
Hortobagyi, Gabriel N. [14 ]
机构：
[1] Ctr Reg Rene Gauducheau, St Herblain, France
[2] Inst Jules Bordet, B-1000 Brussels, Belgium
[3] Sunnybrook Odette Canc Ctr, Toronto, ON, Canada
[4] Univ Toronto, Toronto, ON, Canada
[5] Novartis Pharmaceut, Florham Pk, NJ USA
[6] Med Univ Vienna, Vienna, Austria
[7] Catholic Univ Louvain, UZ Leuven, B-3000 Louvain, Belgium
[8] Macerata Hosp, Dept Oncol, Macerata, MC, Italy
[9] Ironwood Canc & Res Ctr, Chandler, AZ USA
[10] Hop St Sacrement, Quebec City, PQ, Canada
[11] Osaka Natl Hosp, Osaka, Japan
[12] Novartis Pharma AG, Basel, Switzerland
[13] Massachusetts Gen Hosp, Boston, MA 02114 USA
[14] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
BREAST | 2011年 / 20卷
关键词：
D O I：
10.1016/j.breast.2011.08.052
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S30 / S30
页数：1
相关论文
共 50 条
  • [21] Everolimus for postmenopausal women with advanced breast cancer: Updated results of the BOLERO-2 phase III trial.
    Piccart-Gebhart, Martine J.
    Noguchi, Shinzaburo
    Pritchard, Kathleen I.
    Burris, Howard A.
    Rugo, Hope S.
    Gnant, Michael
    Hortobagyi, Gabriel N.
    Melichar, Bohuslav
    Petrakova, Katarina
    Arena, Francis P.
    Xu, Cindy
    Cahana, Ayelet
    Taran, Tanya
    Sahmoud, Tarek
    Lebwohl, David Edward
    Campone, Mario
    Baselga, Jose
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [22] Everolimus for postmenopausal women with advanced breast cancer: Updated results of the BOLERO-2 phase III trial.
    Arena, Francis P.
    Noguchi, Shinzaburo
    Pritchard, Kathleen I.
    Burris, Howard A.
    Rugo, Hope S.
    Gnant, Michael
    Hortobagyi, Gabriel N.
    Latini, Luciano
    Yardley, Denise Aysel
    Melichar, Bohuslav
    Petrakova, Katarina
    Harb, Wael
    Feng, Wentao
    Cahana, Ayelet
    Taran, Tanya
    Campone, Mario
    Baselga, Jose
    Sahmoud, Tarek
    Lebwohl, David Edward
    Piccart-Gebhart, Martine J.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (27)
  • [23] Observational study of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer
    Ottestad, Lars
    Fronth, Line
    Rajendiran, Sajitha
    Aksnes, Liv Hege
    Eikesdal, Hans Petter
    Blix, Egil Store
    Ewertz, Marianne
    ACTA ONCOLOGICA, 2019, 58 (03) : 385 - 387
  • [24] Everolimus Added to Exemestane Reduced Bone Markers and Disease Progression in Bone in Postmenopausal Women with Advanced Breast Cancer: Updated Results From the BOLERO-2 Trial
    Gnant, M.
    Hortobagyi, G. N.
    Rugo, H.
    Burris, H. A.
    Noguchi, S.
    Pritchard, K. I.
    Baselga, J.
    Sahmoud, T.
    Bauly, H.
    Piccart, M.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : S2 - S2
  • [25] Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer The BOLERO-6 Randomized Clinical Trial
    Jerusalem, Guy
    de Boer, Richard H.
    Hurvitz, Sara
    Yardley, Denise A.
    Kovalenko, Elena
    Ejlertsen, Bent
    Blau, Sibel
    Ozguroglu, Mustafa
    Landherr, Laszlo
    Ewertz, Marianne
    Taran, Tetiana
    Fan, Jenna
    Noel-Baron, Florence
    Louveau, Anne-Laure
    Burris, Howard
    JAMA ONCOLOGY, 2018, 4 (10) : 1367 - 1374
  • [26] Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2
    Noguchi, Shinzaburo
    Masuda, Norikazu
    Iwata, Hiroji
    Mukai, Hirofumi
    Horiguchi, Jun
    Puttawibul, Puttisak
    Srimuninnimit, Vichien
    Tokuda, Yutaka
    Kuroi, Katsumasa
    Iwase, Hirotaka
    Inaji, Hideo
    Ohsumi, Shozo
    Noh, Woo-Chul
    Nakayama, Takahiro
    Ohno, Shinji
    Rai, Yoshiaki
    Park, Byeong-Woo
    Panneerselvam, Ashok
    El-Hashimy, Mona
    Taran, Tetiana
    Sahmoud, Tarek
    Ito, Yoshinori
    BREAST CANCER, 2014, 21 (06) : 703 - 714
  • [27] THERAPEUTIC AND ECONOMIC VALUE OF EVEROLIMUS PLUS EXEMESTANE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE, HER2/NEU NEGATIVE ADVANCED BREAST CANCER
    Felix, J.
    Almeida, J.
    Ferreira, D.
    Rabiais, S.
    Vandewalle, B.
    VALUE IN HEALTH, 2015, 18 (07) : A453 - A453
  • [28] Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2
    Shinzaburo Noguchi
    Norikazu Masuda
    Hiroji Iwata
    Hirofumi Mukai
    Jun Horiguchi
    Puttisak Puttawibul
    Vichien Srimuninnimit
    Yutaka Tokuda
    Katsumasa Kuroi
    Hirotaka Iwase
    Hideo Inaji
    Shozo Ohsumi
    Woo-Chul Noh
    Takahiro Nakayama
    Shinji Ohno
    Yoshiaki Rai
    Byeong-Woo Park
    Ashok Panneerselvam
    Mona El-Hashimy
    Tetiana Taran
    Tarek Sahmoud
    Yoshinori Ito
    Breast Cancer, 2014, 21 : 703 - 714
  • [29] BOLERO-2: Efficacy and safety of first-line everolimus plus exemestane in advanced breast cancer.
    Rugo, Hope S.
    Campone, Mario
    Gnant, Michael
    Neven, Patrick
    Pistilli, Barbara
    Baselga, Jose
    Bauly, Hounayda
    Taran, Tanya
    Sahmoud, Tarek
    Hortobagyi, Gabriel N.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (26)
  • [30] ACOSOG Z1031: A randomized phase II trial comparing exemestane, letrozole, and anastrozole in postmenopausal women with clinical stage II/III estrogen receptor-positive breast cancer
    Ellis, M. J.
    Babiera, G.
    Unzeitig, G. W.
    Marcom, P. K.
    Guenther, J. M.
    Deshryver, F. K.
    Allred, D. C.
    Suman, V.
    Hunt, K.
    Olson, J. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18)
12345